354 related articles for article (PubMed ID: 11016962)
1. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.
Marks-Konczalik J; Dubois S; Losi JM; Sabzevari H; Yamada N; Feigenbaum L; Waldmann TA; Tagaya Y
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11445-50. PubMed ID: 11016962
[TBL] [Abstract][Full Text] [Related]
2. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
Zhang S; Zhao J; Bai X; Handley M; Shan F
Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
[TBL] [Abstract][Full Text] [Related]
3. CAR-T cell therapy: current limitations and potential strategies.
Sterner RC; Sterner RM
Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
[TBL] [Abstract][Full Text] [Related]
4. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Jin L; Tao H; Karachi A; Long Y; Hou AY; Na M; Dyson KA; Grippin AJ; Deleyrolle LP; Zhang W; Rajon DA; Wang QJ; Yang JC; Kresak JL; Sayour EJ; Rahman M; Bova FJ; Lin Z; Mitchell DA; Huang J
Nat Commun; 2019 Sep; 10(1):4016. PubMed ID: 31488817
[TBL] [Abstract][Full Text] [Related]
5. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS; Locke FL; Bartlett NL; Lekakis LJ; Miklos DB; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Stiff PJ; Friedberg JW; Flinn IW; Goy A; Hill BT; Smith MR; Deol A; Farooq U; McSweeney P; Munoz J; Avivi I; Castro JE; Westin JR; Chavez JC; Ghobadi A; Komanduri KV; Levy R; Jacobsen ED; Witzig TE; Reagan P; Bot A; Rossi J; Navale L; Jiang Y; Aycock J; Elias M; Chang D; Wiezorek J; Go WY
N Engl J Med; 2017 Dec; 377(26):2531-2544. PubMed ID: 29226797
[TBL] [Abstract][Full Text] [Related]
6. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages.
Gautier EL; Shay T; Miller J; Greter M; Jakubzick C; Ivanov S; Helft J; Chow A; Elpek KG; Gordonov S; Mazloom AR; Ma'ayan A; Chua WJ; Hansen TH; Turley SJ; Merad M; Randolph GJ;
Nat Immunol; 2012 Nov; 13(11):1118-28. PubMed ID: 23023392
[TBL] [Abstract][Full Text] [Related]
7. The chemokine system in diverse forms of macrophage activation and polarization.
Mantovani A; Sica A; Sozzani S; Allavena P; Vecchi A; Locati M
Trends Immunol; 2004 Dec; 25(12):677-86. PubMed ID: 15530839
[TBL] [Abstract][Full Text] [Related]
8. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation CAR T-cell Therapies.
Young RM; Engel NW; Uslu U; Wellhausen N; June CH
Cancer Discov; 2022 Jul; 12(7):1625-1633. PubMed ID: 35417527
[TBL] [Abstract][Full Text] [Related]
10. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
Front Immunol; 2021; 12():732135. PubMed ID: 34925314
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
12. Delivery technologies to engineer natural killer cells for cancer immunotherapy.
El-Mayta R; Zhang Z; Hamilton AG; Mitchell MJ
Cancer Gene Ther; 2021 Sep; 28(9):947-959. PubMed ID: 33888870
[TBL] [Abstract][Full Text] [Related]
13. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
Schmidt P; Raftery MJ; Pecher G
Front Immunol; 2020; 11():611163. PubMed ID: 33488617
[TBL] [Abstract][Full Text] [Related]
14. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
16. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Pomeroy EJ; Hunzeker JT; Kluesner MG; Lahr WS; Smeester BA; Crosby MR; Lonetree CL; Yamamoto K; Bendzick L; Miller JS; Geller MA; Walcheck B; Felices M; Webber BR; Starr TK; Moriarity BS
Mol Ther; 2020 Jan; 28(1):52-63. PubMed ID: 31704085
[TBL] [Abstract][Full Text] [Related]
17. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
Zhu H; Kaufman DS
Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
[TBL] [Abstract][Full Text] [Related]
18. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
19. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
20. Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.
Müller E; Speth M; Christopoulos PF; Lunde A; Avdagic A; Øynebråten I; Corthay A
Front Immunol; 2018; 9():2520. PubMed ID: 30450098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]